Effects of Cranberry Consumption in Vascular Function in Healthy Individuals
- Conditions
- Healthy Men
- Interventions
- Dietary Supplement: Cranberry 1600Dietary Supplement: Cranberry 320Dietary Supplement: Cranberry 960Dietary Supplement: Cranberry deprived supplementDietary Supplement: Cranberry 640Dietary Supplement: Cranberry 1280
- Registration Number
- NCT02517775
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Brief Summary
Accumulating evidence from epidemiological and human intervention studies indicates that the cardiovascular health benefits of diets rich in fruits and vegetables are (in part) related to their (poly)phenol content. Cranberries are rich in (poly)phenols compounds, in particular anthocyanins, but also phenolic acids. At present, a small number of randomized controlled trials investigating the effects of berry (poly)phenols on validated surrogate markers of cardiovascular disease risk has shown promising results. However, to date, very few human studies have specifically investigated the effects of cranberry (poly)phenols on cardiovascular function in healthy subjects. To our knowledge, no study has investigated the time and intake-dependent effect of cranberry consumption on vascular function in healthy subjects. This information is necessary for the planning of long-term studies aiming to assess the potential beneficial effects of cranberries, using optimal amounts at optimal time points. Therefore, this study aims to investigate the potential role of cranberry (poly)phenols in the modulation of vascular function by monitoring changes in vascular function together with the major (poly)phenol derivatives/metabolites in plasma and urine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 10
- healthy male subjects without clinical signs or symptoms of cardiovascular disease
- cardiovascular disease
- acute inflammation
- cardiac arrhythmia
- renal failure
- heart failure (NYHA II-IV)
- diabetes mellitus
- C-reactive protein > 05 mg/dL
- malignant disease
- cranberry allergy/intolerance
- hypotension (≤100 / 60 mm Hg)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cranberry 1600 Cranberry 1600 Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily) Cranberry 320 Cranberry 320 Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily) Cranberry 960 Cranberry 960 Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily) Cranberry deprived supplement Cranberry deprived supplement Placebo comparator: Cranberry deprived supplement Acute intake of 500 mL (1x daily) Cranberry 640 Cranberry 640 Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily) Cranberry 1280 Cranberry 1280 Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
- Primary Outcome Measures
Name Time Method Endothelial function Baseline, on week 1, 2, 3, 4 and 5 postconsumption measured by Flow mediated dilation at 1, 2, 4, 6 and 8 hours after intake
- Secondary Outcome Measures
Name Time Method Heart Rate Baseline, on week 1, 2, 3, 4 and 5 postconsumption measured by SphygmoCor 0, 1, 2, 4, 6 and 8 hours after intake
pulse wave velocity Baseline, on week 1, 2, 3, 4 and 5 postconsumption measured by SphygmoCor at 0, 1, 2, 4, 6 and 8 hours after intake
Central blood pressure Baseline, on week 1, 2, 3, 4 and 5 postconsumption measured by SphygmoCor at 0, 1.5, 4, 6 and 8 hours after intake
Peripheral blood pressure Baseline, on week 1, 2, 3, 4 and 5 postconsumption measured by automatic sphygmomanometer at 0, 1, 2, 4, 6 and 8 hours after intake
Trial Locations
- Locations (1)
Division of Cardiology, Pulmonary Disease and Vascular Medicine, University Hospital Duesseldorf
🇩🇪Duesseldorf, Germany